HFNC therapy is increasingly used as ‘non-invasive’ respiratory support for preterm infants. A 2016 Cochrane Review found that had similar efficacy to NCPAP infants following extubation,1 but further studies were needed, particularly in extremely born <28 weeks' gestation, who are at highest risk of extubation failure. The trial by Uchiyama et al the largest randomised post-extubation infants, ...

The impact of noninvasive positive-pressure ventilation (NIPPV) on pulmonary function studies, quality of life, and survival was assessed in patients with amyotrophic lateral sclerosis. NIPPV did not change the rate of decline of the forced vital capacity (FVC) and forced expiratory volume in the first second (FEV(1)) (2.31 and 2.09 percent-predicted points per month, respectively). NIPPV resul...

Nasal intermittent positive-pressure ventilation (nIPPV) is used for the treatment of respiratory failure in patients with neuromuscular disease. The aim of the present study was to demonstrate that nIPPV may activate nose receptors, the consequence of which being reflex changes in lung resistance. The changes in interrupter resistances (Rint) in response to nIPPV were tested before and after l...

The role of noninvasive positive pressure ventilation (NIPPV) in adult respiratory distress syndrome (ARDS) is controversial, in contrast to its well established benefits in other types of respiratory failure, especially acute exacerbations of chronic obstructive pulmonary disease and cardiogenic pulmonary oedema. We report a case of ARDS caused by Mycoplasma pneumoniae in a 70 year old man, tr...

BACKGROUND The use of noninvasive positive-pressure ventilation (NIPPV) for acute respiratory failure (ARF) has become more widespread over the past decade, but its prescription, use and outcomes in the clinical setting remain uncertain. The objective of this study was to review the use of NIPPV for ARF with respect to clinical indications, physician ordering, monitoring strategies and patient ...

BACKGROUND Optimal timing of noninvasive positive pressure ventilation (NIPPV) initiation in patients with amyotrophic lateral sclerosis (ALS) is unknown, but NIPPV appears to benefit ALS patients who are symptomatic from pulmonary insufficiency. This has prompted research proposals of earlier NIPPV initiation in the ALS disease course in an attempt to further improve ALS patient quality of lif...

NASAL INTERMITTENT POSITIVE pressure ventilation (nIPPV) is a noninvasive modality of ventilatory support that is frequently used for a number of clinical conditions. Suggested applications for nIPPV include the treatment of respiratory distress and apnea of prematurity, sleep apnea syndromes, chronic obstructive pulmonary disease, and as a bridge between mechanical ventilation and unassisted b...

We read with interest the systematic review by Zhao et al. [1] comparing the effect of the high-flow nasal cannula (HFNC) and noninvasive positive pressure ventilation (NIPPV) therapies in acute respiratory failure. Coincidentally, a similar review [2] was also published in Chest recently in which the cohort studies were also included. Both of these two reviews reported that, compared to HFNC, ...

Background Infant respiratory distress syndrome (IRDS) is one of the main causes of serious complications and death in preterm infants. Both Nasal Continuous Positive Airway Pressure (NCPAP) and Nasal Intermittent Positive Pressure Ventilation (NIPPV) are known as the most common treatment strategies for IRDS. The present study intended to compare NCPAP and NIPPV in the treatment of preterm inf...

Non-invasive positive pressure ventilation (NIPPV) for respiratory failure in cystic fibrosis (CF) is frequently used in adults and has been shown to be of benefit to patients with advanced disease in terms of stabilisation of lung function, reduction in symptoms and increased exercise capacity. When used as an adjunct to physiotherapy, NIPPV increases oxygen saturations (SpO2), tidal volume, m...